The need for fast-track, high-quality and low-cost studies about the role of the BCG vaccine in the fight against COVID-19

• Letter to the Editor
• Open Access
• 
  

• Marcos Pereira, 
• Enny Paixão, 
• Anete Trajman, 
• Ramon Andrade de Souza, 
• Marcio Santos da Natividade, 
• Julia M. Pescarini, 
• Susan Martins Pereira, 
• Florisneide Rodrigues Barreto, 
• Ricardo Ximenes, 
• Margareth Dalcomo, 
• Maria Yury Ichihara, 
• Ceuci Nunes, 
• Manoel Barral-Netto & 
• Maurício L. Barreto 

Respiratory Research volume 21, Article number: 178 (2020) 

• details

Abstract

Bacillus Calmette-Guérin (BCG) vaccination is routine and near-universal in many low- and middle-income countries (LMIC). It has been suggested that BCG can have a protective effect on COVID-19 morbidity and mortality. This commentary discusses the limitations of the evidence around BCG and COVID-19. We argue that higher-quality evidence is necessary to understand the protective effect of the BCG vaccine from existing, secondary data, while we await results from clinical trials currently conducted in different settings.

Download PDF